Back Back
Cell No. : Cell Name
RCB1192 : MDA-MB-453  update : 2023/06/30
CommentHuman breast carcinoma established from an effusion. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 65 prior to order.Application consideration
Comment from the depositor
Terms and conditions1) There is no restriction regarding use for basic researches. However, since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ACC 65 prior to order. 2) In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor DSMZ
Year of deposit 1995
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Female
Tissue breast
Disease name breast carcinoma
Classification cancer
History overseas, DSMZ (ACC 65)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_0418
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium L-15 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 1-2 times/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 0 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 82-108(50) : /86(3),87(1),88(7),89(13),90(17),91(5)/
STR(human) OK
deposit info
lot info
Reference information Reference 2
User's Publication 47

To topTop
4957  Siciliano MJ, Barker PE, Cailleau R.  Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker.  Cancer Res  1979  9(3):919-22  PubMed ID: 427779  
2041  Cailleau R, Olive M, Cruciger, Q V  Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.  In Vitro  1978  14:911-5  PubMed ID: 730202   DOI: 10.1007/bf02616120

To topTop
User's Publication
21684  Masuda Y, Yamashita S, Nakayama Y, Shimizu R, Konishi M.  Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.  Biol Pharm Bull  2024  47(4):840-847  PubMed ID: 38616114   DOI: 10.1248/bpb.b23-00802
17582  Sugiura S, Yamahira S, Tamura M, Shin K, Shibuta M, Satoh T, Matsuzawa Y, Fujii G, Yanagawa F, Mutoh M, Yanagisawa M, Kato R, Matsui H.  Automated cell isolation from photodegradable hydrogel based on fluorescence image analysis  Biotechnol Bioeng  2023  Mar 15  PubMed ID: 36919627   DOI: 10.1002/bit.28375
13416  Sagara M, Miyamoto S, Itoh S, Soda Y, Tani K.  Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.  Anticancer Res  2021    PubMed ID: 33419801   DOI: 10.21873/anticanres.14753
20159  Sakabe T, Wakahara M, Shiota G, Umekita Y.  Role of cytoplasmic localization of maspin in promoting cell invasion in breast cancer with aggressive phenotype.  Sci Rep  2021  11(1):11321  PubMed ID: 34059749   DOI: 10.1038/s41598-021-90887-z
16735  Okada H, Mimura M, Tomita S, Kurita R.  Affinity Diversification of a Polymer Probe for Pattern-recognition-based Biosensing Using Chemical Additives  Anal Sci   2021  37(5):713-719  PubMed ID: 33518589   DOI: 10.2116/analsci.20SCP23
11952  Kimura R, Yoshimaru T, Matsushita Y, Matsuo T, Ono M, Park JH, Sasa M, Miyoshi Y, Nakamura Y, Katagiri T.  The GALNT6‑LGALS3BP axis promotes breast cancer cell growth.  Int. J. Oncol.  2020    PubMed ID: 31894262   DOI: 10.3892/ijo.2019.4941
12064  Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.  Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.  J. Surg. Res.  2020    PubMed ID: 32092597   DOI: 10.1016/j.jss.2019.12.040
13226  Muguruma M, Teraoka S, Miyahara K, Ueda A, Asaoka M, Okazaki M, Kawate T, Kuroda M, Miyagi Y, Ishikawa T.  Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines.  Biochem Biophys Res Commun  2020    PubMed ID: 32958246   DOI: 10.1016/j.bbrc.2020.08.075
13770  Kim H, Hoshi M, Iijima M, Kuroda S, Nakamura C.  Development of a universal method for the measurement of binding affinities of antibody drugs towards a living cell based on AFM force spectroscopy  Anal Methods  2020  12(22):2922-2927  PubMed ID: 32930215   DOI: 10.1039/d0ay00788a
14854  Terasaki A, Kurokawa H, Ito H, Komatsu Y, Matano D, Terasaki M, Bando H, Hara H, Matsui H.  Elevated Production of Mitochondrial Reactive Oxygen Species via Hyperthermia Enhanced Cytotoxic Effect of Doxorubicin in Human Breast Cancer Cell Lines MDA-MB-453 and MCF-7  Int J Mol Sci  2020  21(24):9522  PubMed ID: 33333736   DOI: 10.3390/ijms21249522
11511  Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.  Nature  2019    PubMed ID: 30971826   DOI: 10.1038/s41586-019-1103-9
11524  Ueda A, Oikawa K, Fujita K, Ishikawa A, Sato E, Ishikawa T, Kuroda M, Kanekura K.  Therapeutic potential of PLK1 inhibition in triple-negative breast cancer.  Lab. Invest.  2019    PubMed ID: 30996295   DOI: 10.1038/s41374-019-0247-4
11563  Kawase A, Inoue Y, Nakazaki S, Koizumi E, Iwaki M.  Radixin knockdown improves the accumulation and efficiency of methotrexate in tumor cells.  Oncol. Rep.  2019    PubMed ID: 31115547   DOI: 10.3892/or.2019.7162
14819  Takayama M, Takatsu H, Hamamoto A, Inoue H, Naito T, Nakayama K, Shin HW.  The cytoplasmic C-terminal region of the ATP11C variant determines its localization at the polarized plasma membrane  J Cell Sci   2019  132(17):jcs231720.  PubMed ID: 31371488   DOI: 10.1242/jcs.231720
11228  Ichihara H, Okumura M, Tsujimura K, Matsumoto Y.  Theranostics with Hybrid Liposomes in an Orthotopic Graft Model Mice of Breast Cancer.  Anticancer Res.  2018    PubMed ID: 30275183   DOI: 10.21873/anticanres.12900
4120  Miyagawa Y, Matsushita Y, Suzuki H, Komatsu M, Yoshimaru T, Kimura R, Yanai A, Honda J, Tangoku A, Sasa M, Miyoshi Y, Katagiri T.  Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer.  Int. J. Oncol.  2018    PubMed ID: 29512727   DOI: 10.3892/ijo.2018.4301
4288  Khatun A, Shimozawa M, Kito H, Kawaguchi M, Fujimoto M, Ri M, Kajikuri J, Niwa S, Fujii M, Ohya S.  Transcriptional Repression and Protein Degradation of the Ca2+-Activated K+ Channel KCa1.1 by Androgen Receptor Inhibition in Human Breast Cancer Cells.  Front Physiol  2018    PubMed ID: 29713287   DOI: 10.3389/fphys.2018.00312
4376  Fujimoto M, Kito H, Kajikuri J, Ohya S.  Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl- /H+ transporter inhibition in human breast cancer cells.  Cancer Sci.  2018  109(9):2781-2791  PubMed ID: 29949674   DOI: 10.1111/cas.13715
9925  Fujimoto M, Inoue T, Kito H, Niwa S, Suzuki T, Muraki K, Ohya S.  Transcriptional repression of HER2 by ANO1 Cl- channel inhibition in human breast cancer cells with resistance to trastuzumab.  Biochem. Biophys. Res. Commun.  2017  482:188-194  PubMed ID: 27838298   DOI: 10.1016/j.bbrc.2016.11.033
10445  Yamaguchi H, Ito Y, Miura N, Nagamura Y, Nakabo A, Fukami K, Honda K, Sakai R.  Actinin-1 and actinin-4 play essential but distinct roles in invadopodia formation by carcinoma cells.  Eur. J. Cell Biol.  2017  96:685-694  PubMed ID: 28797528   DOI: 10.1016/j.ejcb.2017.07.005
5680  Ginting TE, Suryatenggara J, Christian S, Mathew G.  Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.  Oncolytic Virother  2017  6:21-30  PubMed ID: 28293547   DOI: 10.2147/OV.S123292
14384  Miyasato Y, Shiota T, Ohnishi K, Pan C, Yano H, Horlad H, Yamamoto Y, Yamamoto-Ibusuki M, Iwase H, Takeya M, Komohara Y.  High density of CD204-positive macrophages predicts worse clinical prognosis in patients with breast cancer  Cancer Sci  2017  108(8):1693-1700  PubMed ID: 28574667   DOI: 10.1111/cas.13287
9818  Kanzaki H, Shinohara F, Suzuki M, Wada S, Miyamoto Y, Yamaguchi Y, Katsumata Y, Makihira S, Kawai T, Taubman MA, Nakamura Y.  A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.  Sci Rep  2016  6:32259  PubMed ID: 27573075   DOI: 10.1038/srep32259
9880  Poulose AC, Veeranarayanan S, Mohamed MS, Aburto RR, Mitcham T, Bouchard RR, Ajayan PM, Sakamoto Y, Maekawa T, Kumar DS.  Multifunctional Cu2-xTe Nanocubes Mediated Combination Therapy for Multi-Drug Resistant MDA MB 453.  Sci Rep  2016  6:35961  PubMed ID: 27775048   DOI: 10.1038/srep35961
9992  Khatun A, Fujimoto M, Kito H, Niwa S, Suzuki T, Ohya S.  Down-Regulation of Ca2+-Activated K⁺ Channel KCa1.1 in Human Breast Cancer MDA-MB-453 Cells Treated with Vitamin D Receptor Agonists.  Int J Mol Sci  2016  17:  PubMed ID: 27973439   DOI: 10.3390/ijms17122083
12882  Kikuchi M, Yamashita K, Waraya M, Minatani N, Ushiku H, Kojo K, Ema A, Kosaka Y, Katoh H, Sengoku N, Enomoto T, Tanino H, Sawanobori M, Watanabe M.  Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer  Oncotarget  2016  7(2):1741-53.  PubMed ID: 26646320   DOI: 10.18632/oncotarget.6480
7226  Subramanian N, Kanwar JR, Kanwar RK, Krishnakumar S.  Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.  Nucleic Acid Ther  2015  25:317-22  PubMed ID: 26334953   DOI: 10.1089/nat.2015.0550
7287  Iida R, Ueki M, Yasuda T.  Identification of interacting partners of Human Mpv17-like protein with a mitigating effect of mitochondrial dysfunction through mtDNA damage.  Free Radic. Biol. Med.  2015  87:336-45  PubMed ID: 26165189   DOI: 10.1016/j.freeradbiomed.2015.07.008
9408  Yasunori Sato, Naoto Sasaki, Megu Saito, Nao Endo, Fumihiko Kugawa, Akemichi Ueno  Luteolin Attenuates Doxorubicin-Induced Cytotoxicity to MCF-7 Human Breast Cancer Cells  Biol Pharm Bull  2015  38(5):703-9  PubMed ID: 25947916   DOI: 10.1248/bpb.b14-00780
5833  Sato M, Muguruma N, Nakagawa T, Okamoto K, Kimura T, Kitamura S, Yano H, Sannomiya K, Goji T, Miyamoto H, Okahisa T, Mikasa H, Wada S, Iwata M, Takayama T.  High antitumor activity of pladienolide B and its derivative in gastric cancer.  Cancer Sci  2014  105(1):110-6  PubMed ID: 24635824   DOI: 10.1111/cas.12317
15803  M. Sheikh Mohamed, Srivani Veeranarayanan, Hiroaki Minegishi, Yasushi Sakamoto, Yasuhiro Shimane, Yutaka Nagaoka, Atsushi Aki, Aby Cheruvathoor Poulose, Akinobu Echigo, Yasuhiko Yoshida, Toru Maekawa, D. Sakthi Kumar  Cytological and Subcellular Response of Cells Exposed to the Type-1 RIP Curcin and its Hemocompatibility Analysis  Scientific Reports  2014  4    DOI: 10.1038/srep05747
17110  Masanari Umemura, Ayako Makino, Itaru Sato, Xianfeng Feng, Kayoko Oda, Makoto Ohtake, Satoshi Izuka, Maki Iwai, Kosuke Matsuo, Haruki Eguchi, Yoshihiro Ishikawa  Abstract 5399: A novel treatment for triple-negative breast cancer using intrinsic magnetized paclitaxel  Cancer Research  2014  74:5399-5399    DOI: 10.1158/1538-7445.am2014-5399
14401  Yamaguchi Y, Deng D, Sato Y, Hou YT, Watanabe R, Sasaki K, Kawabe M, Hirano E, Morinaga T.  Silicate fiber-based 3D cell culture system for anticancer drug screening  Anticancer Res  2013  33(12):5301-9  PubMed ID: 24324063  
17165  Nakagawa S, Matsuoka Y, Ichihara H, Yoshida H, Yoshida K, Ueoka R.  Therapeutic effects of autologous lymphocytes activated with trastuzumab for xenograft mouse models of human breast cancer  Biol Pharm Bull  2013  36(5):861-5  PubMed ID: 23649343   DOI: 10.1248/bpb.b12-01084
7842  Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F, Murakami Y.  Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer.  Breast Cancer  2012  19:242-52  PubMed ID: 21526423   DOI: 10.1007/s12282-011-0272-7
8681  Shinya Shimoda, Hideaki Ichihara, Yoko Matsumoto, Ryuichi Ueoka  Nanoparticles of Hybrid Liposomes for the Inhibition of Breast Tumor Growth along with Apoptosis  Chemistry Letters  2009  38:134-135    DOI: 10.1246/cl.2009.134
18455  Shimoda S, Ichihara H, Matsumoto Y, Ueoka R.  Chemotherapy with hybrid liposomes for human breast tumors along with apoptosis in vivo  Int J Pharm  2009  372(1-2):162-8  PubMed ID: 19429276   DOI: 10.1016/j.ijpharm.2009.01.011
18469  Tsuna M, Kageyama S, Fukuoka J, Kitano H, Doki Y, Tezuka H, Yasuda H.  Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma  Anticancer Res  2009  29(7):2547-54  PubMed ID: 19596927  
5877  Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S.  FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.  Biol Pharm Bull  2009  32(7):1148-54  PubMed ID: 19571376   DOI: 10.1248/bpb.32.1148
12771  Azumi K, Ikeda Y, Takeuchi T, Nomura T, Sabau SV, Hamada J, Okada F, Hosokawa M, Yokosawa H.  Localization and characterization of γ-glutamyl cyclotransferase in cancer cells  Mol Med Rep  2009  2(3):385-91  PubMed ID: 21475839   DOI: 10.3892/mmr_00000110
18925  Hata Y, Etoh T, Inomata M, Shiraishi N, Nishizono A, Kitano S.  Efficacy of oncolytic reovirus against human breast cancer cells  Oncol Rep  2008  19(6):1395-8  PubMed ID: 18497942  
5012  Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.  Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.  Hum Mol Genet  2006  15(6):821-30  PubMed ID: 16439445   DOI: 10.1093/hmg/ddl001
2763  Ghosh, Mila, Koike, Naoto, Tsunoda, Shin-Ichi, Hirano, Takashi, Kaul, Sunil, Kashiwagi, Hironobu, Kawamoto, Toru, Ohkohchi, Nobuhiro, Saijo, Kaoru, Ohno, Tadao, Miwa, Masanao, Todoroki, Takeshi  Characterization and genetic analysis in the newly established human bile duct cancer cell lines.  Int J Oncol  2005  26:449-56  PubMed ID: 15645130  
3023  Nishikawa, Kazuhiro, Satoh, Haruna, Hirai, Ayako, Suzuzki, Kazuyuki, Asano, Ryuji, Kumadaki, Itsumaro, Hagiwara, Kiyokazu, Yano, Tomohiro  alpha-Tocopheryloxybutyric acid enhances necrotic cell death in breast cancer cells treated with chemotherapy agent.  Cancer Lett  2003  201:51-6  PubMed ID: 14580686   DOI: 10.1016/s0304-3835(03)00462-2
3040  Satoh H, Nishikawa K, Suzuki K, Asano R, Virgona N, Ichikawa T, Hagiwara K, Yano T.  Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent.  Res. Commun. Mol. Pathol. Pharmacol.  2003  113-114:149-58  PubMed ID: 15686114  
3019  Akazawa, Akihiko, Nishikawa, Kazuhiro, Suzuki, Kazuyuki, Asano, Ryuji, Kumadaki, Itsumaru, Satoh, Haruna, Hagiwara, Kiyokazu, Shin, Sung Jae, Yano, Tomohiro  Induction of apoptosis in a human breast cancer cell overexpressing ErbB-2 receptor by alpha-tocopheryloxybutyric acid.  Jpn J Pharmacol  2002  89:417-21  PubMed ID: 12233821   DOI: 10.1254/jjp.89.417
6400  Hatano H, Kawashima H, Ogose A, Hotta T, Endo N.  A PCR-ELISA assay for the detection of disseminated osteosarcoma cells in a mouse metastatic model.  J Orthop Sci  2001  6(3):269-75  PubMed ID: 11484122   DOI: 10.1007/s007760100046

Back Back Return Top Page